Physician profile
James M Wicks
NPI 1275553331
$9,791.44
in general payments reported to CMS, 2019-2025
25 companies · $2,702 in 2025
The $2,702 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $170 · 2021: $1,190 · 2022: $706 · 2023: $1,944 · 2024: $2,633 · 2025: $2,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,278.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,755.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,379.08 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Novo Nordisk INC | $1,208.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,137.45 | 2019-2025 | Opsumit, Xarelto, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,043.69 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $468.72 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $458.14 | 2021-2025 | Linq II, Selectsecure, Corevalve Evolut R |
| Pfizer INC. | $437.82 | 2022-2025 | |
| Amgen INC. | $368.24 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $225.16 | 2024-2025 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $199.20 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $171.96 | 2019-2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $161.65 | 2022 | |
| Bridgebio Pharma, INC. | $143.02 | 2025 | Attruby |
| Lilly USA, LLC | $115.05 | 2023-2025 | Mounjaro, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $113.68 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.30 | 2020-2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $80.43 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $69.35 | 2022-2023 | Arcalyst |
| Abbott Laboratories | $52.53 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Kiniksa Pharmaceuticals International, Plc | $26.94 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $21.17 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.20 | 2025 | |
| Merck Sharp & Dohme LLC | $19.20 | 2025 | Verquvo |
| Esperion Therapeutics, INC. | $17.92 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.